Related Experiment Video
Updated: Aug 30, 2025

Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
A Comprehensive Description of Hypoxia-inducible Factor 2α Inhibitors as Anticancer Agents: A Mini-review
Hongyuan Lu1, Yan Zhu1, Wenwu Liu2
1Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, People's Republic of China.
Abstract:
Targeting the tumor microenvironment is a promising strategy to prevent metastasis, overcome acquired drug resistance, and improve the therapeutic effect. Hypoxia is one of the characteristics of the tumor microenvironment, which is mainly regulated by hypoxia-inducible factors. Hypoxia-inducible factors (HIFs) including HIF-1α, HIF-2α, and HIF-3α, of which HIF-2α has assumed a more important role in tumor hypoxia environment. It has been demonstrated that HIF-2α plays an important role in tumor diseases, including renal cell carcinoma, breast cancer, non-small cell lung cancer, and gastric cancer, among others. Therefore, targeting HIF-2α has become one of the important strategies for treating cancers. HIF-2α inhibitors can be divided into two categories: specific inhibitors and non-specific inhibitors. The former includes synthetic monomer compounds and traditional Chinese medicine extracts. In this review, we summarized, classified, and discussed current research on the structure, structure-activity relationship (SAR), and pharmacology of HIF-2α inhibitors, which is helpful to the rational design of effective drugs for various types of malignant tumors.
Insights
Targeting hypoxia-inducible factor-2 alpha (HIF-2α) is crucial for cancer therapy. This review details HIF-2α inhibitors, aiding the development of novel anti-cancer drugs.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The tumor microenvironment, characterized by hypoxia, promotes cancer progression and drug resistance.
- Hypoxia-inducible factors (HIFs), particularly HIF-2α, are key regulators in tumor hypoxia.
- HIF-2α is implicated in various cancers, including renal cell carcinoma, breast, lung, and gastric cancers.
Approach:
- This review categorizes and analyzes current research on HIF-2α inhibitors.
- It focuses on the structure, structure-activity relationships (SAR), and pharmacology of these inhibitors.
- Both specific (synthetic compounds, traditional Chinese medicine extracts) and non-specific inhibitors are discussed.
Key Points:
- HIF-2α plays a significant role in multiple tumor types.
- Targeting HIF-2α is a promising therapeutic strategy.
- Understanding SAR is vital for designing effective HIF-2α inhibitors.
Conclusions:
- HIF-2α inhibitors represent a critical area of cancer drug development.
- This review provides a comprehensive overview to guide the rational design of new anti-cancer agents.
- Further research into HIF-2α inhibitors can lead to improved cancer treatments.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Regulation of Angiogenesis and Blood Supply
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...

